glp 1 addiction IUPHAR review – Glucagon-like peptide-1 (GLP-1) and substance use disorders: An emerging pharmacotherapeutic target GLP-1 Anti-Obesity Rx and Alcohol
Description
What are the long-term effects on muscle mass, bone density, or neurobiology
You know that coverage depends on your diagnosis, your plans formulary, and the specific way your plan has implemented CMSs 2026 guidance on GLP-1 medications
That may change based on the results of a Phase 3 trial completed last year, in which patients who took 25-milligram semaglutide pills lost an average 13.6% of their body weight after 64 weeks, compared to 2.2% who took a placebo
[DOI] [PubMed] [Google Scholar] 8
Month 3: Should GLP-1 Side Effects Be Gone by Now
